Background: Financial analysis (budget impact analysis, BIA) is increasingly required by decision-makers to ascertain the macroeconomic consequences of new product reimbursement in addition to proof of cost-effectiveness. Poland is in the process of drafting country-specific guidelines for BIA, positioned as complementary to economic evaluation in decision-making Objectives: The aim of this article is to present the Polish project and compare it with currently available guidance. Methods: A checklist was developed that focuses on issues that are unique to BIA. An analysis of the differences between different national guidelines and their Polish counterparts was subsequently undertaken. Results: The Polish project of BIA guidelines is composed of two sections. The first section presents the objective, the use of BIA, the responsibility for the preparation, and
Introduction
In 1970, Toffler [1] described a world of "Future Shock," in which advances in technology outpaced society's ability to cope with them. The many resultant problems included ethical, economic, and societal challenges about how to allocate the benefits of this brave new world of high technology. In the field of health care this challenge brings into sharper focus the concept of the provision of quality health care at an affordable cost. The rapid growth of health-care expenditures, coupled with slowdown in the growth of the general economy, has led to increased interest in health-economic and financial evaluation of health-care programs. Both of these approaches independently inform health-care decision-makers: the health-economic evaluation, which demonstrates the cost-effectiveness, or value for money, of new intervention, may assist the prioritization of interventions, advocating efficiency maximization as a central objective; the financial analysis, budget impact analysis (BIA), which provides insight into the budget impact of the inclusion of the new intervention, addresses the issue of affordability. The cost-effectiveness and affordability has been widely labeled as the "fourth and fifth hurdle" to market, in addition to the traditional three hurdles of safety, efficacy, and quality, required for the licensing of new medical technology.
If medical decision-making is going to be based on economic data, guidance must be forthcoming. Without it, such decisions run the risk of degenerating into ill-informed negotiations based on evidence of a variable quality. For several years a growing number of countries have developed guidelines that outline issues in the design and carrying out of health-economic studies [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . Unfortunately, although an increasing number of agencies have recognized the potential for BIA, guidance for such analysis has been slow to develop. Existing guidance are generally limited in detail, unclear, and variable in terms of defining what constitutes a BIA.
Poland is in the process of drafting countryspecific guidelines for BIA, positioned as complementary to health economic evaluation in decision-making. The aim of this article is to present the project of Polish guidelines for conducting BIA and compare it with existing international guidance, highlighting areas of agreement and dissent.
Background
Pharmaceutical pricing and reimbursement in Poland have been based until recently on the traditional clinical trial outcomes, efficacy, safety, and quality parameters, used for registration. The main response to rising costs over the past decade has been the introduction of cost-containment policies, such as reference price system, based on classification of pharmaceuticals into groups of interchangeable drugs and setting the fixed refund price according to the lowest priced drug in the cluster.
At the end 2001, Poland implemented the new Pricing Law [20] to improve the functionality of the existing pricing and reimbursement system and to bring Poland into line with the EU's Transparency Directive. In this regulation, requirements for justification of the proposed price and description of impact of the drug on direct treatment costs are specified [20] . The first one can be interpreted as the first step toward taking advantage of health economic evaluation the second one addresses the problem of affordability. The lack of clear interpretation and the lack of suggestions about approaches/calculations as part of legal framework raised issues in both filling out and evaluation of applications submitted for reimbursement. In an attempt to bridge this gap, proposals for guidelines for conducting health economic evaluation and guidelines for conducting BIA have been prepared by representatives of academy and government. The Polish projects, after consultation with international experts, were published in a Polish professional pharmacoeconomic journal [21, 22] , presented on Web sites (http://www.farmakoekonomika.edu.pl and http://www.decyzjemedyczne.org.pl) and during Polish and international meetings. Polish Society for Medical Decision Making, the professional association for physicians, initiated consultation with representatives from all medical faculties, the Polish Medical Chamber, associations of health care managers, and associations of local and international manufacturers.
The aim of the projects is to stimulate the provision of standardized, reliable, and good quality information for target audience-policy makers and purchasers of health care services. Among other things, the guidelines recognize the obstacle and difficulties in conducting health economic and budget impact studies and the lack of available data and by serving as reference material stimulate the development in accordance with the worldwide trend toward economic system of reimbursement.
Positioning of BIA in Relation to Health Economic Analysis
BIA should be positioned as complementary to health economic evaluation and viewed as working in parallel [23] . The health economic analysis evaluates, from the societal perspective, the possible inclusion of a drug in light of the criterion of costeffectiveness after determining the therapeutic added value. The financial analysis looks at the budgetary macroconsequences on the possible inclusion of the drug. Insight into these budgetary consequences was necessary in making the choice within the unavoidable budgetary restrictions. The two methods might work together by firstly identifying cost-effective drugs, then by assessing potential budget impact of the possible inclusion of a drug or by reversing this sequence and carrying out the financial analysis first so there and then it could be immediately determined whether there was a sufficient budget available for reimbursement.
The Reason for Special Guidelines for Conducting BIA
The need for carrying out the financial analysis has been mentioned in Appendix 1 of the project of Polish guidelines for conducting health economic evaluations, but since the health economic guidelines themselves deal purely with the scientific methodology of health economic research, it was believed that the recommendations regarding financial analysis should be treated as separate guidelines. This arrangement does not imply any difference in the relative importance of the two analyses, but was chosen to accentuate the difference between the two analyses and to stress that financial analysis should not be regarded as a variant of the health economic analysis conducted from a purchaser perspective. Admittedly both of them may share many of the same data, but they differ in their scope and reporting of the results.
The main advantage of special guidelines for carrying out financial analysis is to establish principles for best practice in designing and implementing financial analysis. For the financial analysis, data on the following will be required: descriptive epidemiology, data on incidence and prevalence, the patient group that is indicated for the drug and the anticipated substitution effects, the use of the drug, its price, and total treatment costs. This ensures that the financial analysis is based on incidence and prevalence statistics for the disease rather than on costs per "treatment/ patient." It is vital to define accurately, scrutinize carefully, and refine this type of analysis when the Committee of Drug Management takes into account among other criteria "the influence on direct costs of treatment" in accordance with the new Polish Pricing Law.
Information Covered by the Project of Polish Guidelines for Conducting BIA
The present project of guidelines is composed of two sections. The first section presents the objective, the use of BIA, the responsibility for the preparation, and the target audience. The second section presents important methodological aspects that researchers ought to keep in mind when carrying out BIA. The full version of the project is available on the Internet (http://www.decyzjemedyczne.org. pl) and is summarized in Table 1 . We will focus here on some aspects that might be important in the interpretation and implementation of guidelines for the parties involved. The impact of the decision on the reimbursement of a given drug on:
The health-care budget for drugs; The health-care budget (as total).
Use and status BIA must be performed on all pharmaceutical products for which an application for reimbursement is submitted, except: 1) pharmaceutical products with the same active ingredient as in a pharmaceutical product for which reimbursement has already been granted, including generic pharmaceuticals, parallel-imported preparations, and preparations in new packaging; and 2) pharmaceutical products for which a new formulation quite clearly does not change the costs and health effects of treatment.
Responsibility for the preparation Reimbursement applicant.
Target audience
Minister of Health.
Methodology
General remarks Transparency BIA should be transparent and allow for understanding of all input assumptions and relations between the variables used in the analyses and the resulting outcomes data on a pharmaceutical agent and its use.
Data sources
Key data for the BIA (e.g., epidemiological data, data on resource use, and unit costs; therapy probably replaced by new drug; target population) should be country-specific. The selection of unit costs attached to resource use data should be consistent with the study perspective. The data on the influence of new therapy on mortality, progression of disease, events rates (e.g., side effects) may come from various sources, not necessarily country-specific, but must first be "translated" to the Polish situation. Relevant data should be searched, appraised, and presented according to the principles and methods of evidencebased medicine and systematic review. The selection of sources used should be justified.
Perspective Public purchaser.
Time horizon Annual financial implications to the health-care budget (for drugs as well total) until the proposed drug is predicted to have achieved a peak or stable market share or for at least 2 years after the date of listing on the reimbursement list.
Target population Population defined based on the approved indication and also subgroups defined on the basis on potential differences in efficacy, costs, and/or preferences.
Presentation of results
Monetary and natural units and impact on service.
Probability of redeploying resources
Models used in the BIA should predict the probability of redeploying any labor or capital savings to other areas of care and predict how the savings will be realized in time.
Sensitivity analysis At a minimum one-way sensitivity analyses to determine where uncertainty or lack of agreement about some key-parameter's value or the functional form of the model could have a substantial impact on conclusion. Inputs such as diffusion rate and probability of redeploying resources should be varied in any interactive model.
Detailed remarks
Data on a pharmaceutical agent and its use.
Estimation of the use of the proposed drug and other drugs, which are prescribed as a part of the treatment of the drug suggested for reimbursement or will probably be used less often in the target population after placing the drug on the reimbursed drugs list because of therapeutic indications and side effects of the current treatment.
Formulas for estimation of the impact of the decision on the reimbursement of a given drug on the health-care budget for drugs and the health-care budget (as total).
Objective, Use of Pharmacoeconomic Analyses, Responsibility for Carrying on the Study, and Target Audience
The first target in the process of implementation of budget impact arguments into rational decisionmaking in Poland are pharmaceuticals because although their share in total health-care expenditure is relatively low, they come under specific legal regulations [20] . The aim of BIA is to measure the impact of the reimbursement decision of a given drug on the budget for drugs and the health-care budget overall. BIA must be performed on all pharmaceutical products for which an application for reimbursement is submitted, except: 1) pharmaceutical products with the same active ingredient as in a pharmaceutical products for which reimbursement has already been granted, including generic pharmaceuticals, parallel-imported preparations and preparations in new packaging; and 2) pharmaceutical products for which a new formulation quite clearly does not change the costs and health effects of treatment. BIA is especially useful for decisionmaking concerning pharmaceutical products with earlier not reimbursed indications or belonging to a new therapeutic class of products, which were not reimbursed earlier. This suggests a particular role for BIA in the reimbursement of new products with an anticipated therapeutic added value compared with existing treatments. Argumentation raised from this evaluation is important, however, it is not the only element in the complex decision-making process.
Responsibility for the preparation, financing, and carrying out of BIA rests with the reimbursement applicants, because they are obliged to submit information requested by Committee of Drug Management within Ministry of Health. In this context it is important to emphasize the role of guidelines, which provide clear instructions on how these studies must be carried out and ensure research is performed correctly. The primary target of BIA is the Minister of Health, who decides whether the drug will be included in the reimbursement list.
Methodology
Methodological guidelines have been classified into general and detailed remarks. General remarks raise a series of issues that should be considered and addressed in developing a BIA; detailed remarks specify what data must be submitted and which method best ensures comparison between such evaluations and also significantly reduce the possibility of misleading conclusions.
General Remarks
Transparency . BIA should be transparent and allow for understanding of all input assumptions and relations between the variables used in the analyses and the resulting outcomes. The predictive model should be made as interactive as possible. It improves the credibility of the research, especially in the case when responsibility for preparation, financing, and carrying out of BIA has been shifted to the sponsor of a new drug. Accessibility of the model allows the decision-makers to assess the scenarios and to undertake their own sensitivity analysis.
Data sources . The source of all data, as well as additional assumptions made in the absence of "real" data, should be clearly stated. Key data for the BIA, for example, epidemiological data, data on resource use and unit costs, therapy probably replaced by new drug, and target population, should be country-specific. The selection of unit costs attached to resource use data should be consistent with the study perspective. The data on the influence of new therapy on mortality, progression of disease and events rates, for example, side effects, may come from various sources, not necessarily country-specific, but must first be "translated" to the Polish situation. Relevant data should be searched, appraised, and presented according to the principles and methods of evidence-based medicine and systematic review. The selection of sources used should be justified.
When resources are measured in a clinical trial it is important to distinguish between resources used in routine practice and those used only in the clinical trial setting. Protocol-driven costs should be excluded from analysis.
Decision-makers must accept that assumptions will inevitably be involved in predicting the rate of adoption of the new therapy before it has been introduced into the health service. Manufacturers should provide the basic information: volume of supplies in the period preceding the submission of the application and declared for the future, structure, and volume of sales in Poland.
Perspective . As the objective of BIA is to measure the impact of the reimbursement decision of a given drug on the health-care budget for drugs and the health-care budget overall, the study perspective should be that of the public purchaser-the key audience for such analyses. Given that society as a whole, through contributions, is responsible for providing much of the public finance used in healthcare purchasing, productivity costs, if they are significant, or unpaid caregivers costs could be included in BIA, provided that the relevance of nonhealth-care costs and benefits to the public purchasing bodies is considered. In most cases public health service purchasers have little opportunity to take any advantage of gains in nonhealth settings or even beyond their own department. Consequently, owing to our inability to transfer savings from beyond the health-care service, the societal approach is not suitable for BIA.
Time horizon . Time horizon of BIA will be influenced by the interest and needs of the target audience, the therapy under investigation, the nature of benefits accrued, and the diffusion rate of the new therapy. Ideally, time horizon for the BIA should be until the proposed drug is predicted to have achieved a peak or stable market share. According to the project of Polish guidelines for conducting BIA, annual financial implications to the health-care budget, for drugs as well as total, to this time horizon or for at least 2 years after the date of listing on the reimbursement list should be estimated. Because the diffusion rate is one of the key uncertainties in attempting to assess the budget impact of new therapy, sensitivity analysis should always include a sensitivity analysis on the diffusion rate.
Target population . The target population for BIA is defined based on the approved indication(s). If the drug is to be reimbursed only in the case of some indications (in Poland, there exists a list of drugs and medical materials for specified severe, chronic, and mental illness), the target population is defined based on the indications, which are significant for the reimbursement. If based on the difference in effectiveness, costs, and/or preferences, a subpopulation can be distinguished, smaller than the population determined by the registered drug indications; such subpopulation should be isolated and a financial analysis should be conducted for the general population as well as for the subpopulation. Given the resource constraints, evidence emerging from such subpopulation studies may allow for introducing narrower restrictions on use of several new medicines than those specified in the regulatory approval.
To meet the needs of health-care decision-maker it would also be advisable to discuss in BIA the potential off-label use of the new drug. Although it is hard to make prediction about this phenomenon, it is suggested that a justifiable baseline assumption should be included in any analysis along with additional scenarios to allow for sensitivity analysis. Although this may introduce some complexity into predictive modeling, ultimately it should produce results that are more applicable to health-care decision-making and can be involved in developing preventive mechanisms.
Cost assessment . In an attempt to standardize the costing methods recently, the separate project of Polish guidelines for costing have been issued, to supplement previous guidelines for conducting health economic and BIA evaluation with more precise information about design, performance, and assessment of cost calculations and to introduce the proposal of standard list of costs [24] . Key issues in relation to BIA will be discussed in more detail.
The approaches to measurement and evaluation of costs vary along a spectrum of specificity. The selection of methodology depends on the aim and the specific setting of the study and should be made by the researcher. Nevertheless, the choice of a specific methodology should follow standard recommendations.
Microcosting and gross-costing can be used within a single analysis. In general, microcosting will be more important for aspects of the alternatives under consideration that are likely to diverge in cost; gross-costing is acceptable when using a more exact microcost estimate cost that will not significantly affect the analysis. The identification of units of resources used raises two questions: what types of resource use are relevant for the disease or intervention studied and to what level of detail do they have to be measured and valued separately?
The costs in BIA should be estimated in terms of the payments actually made or the savings actually realized by the public purchaser. These involve different unit prices from those recommended in health-care evaluation, which reflect the opportunity cost rather than charges or tariffs. Consequently, tariffs and other prices in the health-care sector are applied. The use of standard unit costs results in the decrease of differences in unit costs estimates between studies and is recommended in the case of formal appraisal studies for reimbursement purposes. For the units with the largest contribution to total or incremental costs, however, a more detailed costing approach might still be necessary, that is, direct calculation of unit costs.
Results should be reported both in natural and in monetary units. This helps decision-makers to judge whether reduced natural units of resources, for example, hospital beds or nursing time, are possible to redeploy to other areas of care and hence mon-etary savings could be realized. In some cases, the quantitative impact of the new intervention on the budget may even be of a secondary importance to the impact on the current use of resources such as general practitioner consultations and nursing care.
The probability of redeploying resources is an issue that deserves special attention. Many interventions will have an impact on health-care service use, reduction in surgery, bed days, consultations, etc., and although it is desirable to emphasize this fact to show the "value" of the treatment, it must be balanced with the sphere of interest of decisionmakers: whether or not real saving is accrued. Therefore, if possible, the models used in the BIA should predict the probability of redeploying any labor or capital savings to other areas of care and predict how the savings will be realized in time. Decision-makers must accept that assumptions will inevitably be involved in predicting the probability of redeploying resources and should be willing to discuss the validity of these assumptions.
Depending on the nature of the new intervention, it might be important to describe the preconditions of its effective introduction, for example, the need for training of medical staff, development of new clinical guidelines, diagnostic facilities, etc. Financial requirements for these preconditions should be summarized.
Sensitivity analysis. The impact of uncertain factors
on final results should be tested using sensitivity analysis. Two major sources of uncertainty are distinguished: parameter uncertainty, uncertainty about the true numerical values of the parameters used as inputs, and model uncertainty, model structure uncertainty, and modeling process uncertainty. At a minimum, the analyst should conduct one-way sensitivity analyses to determine where uncertainty or lack of agreement about some key parameter's value or the functional form of the model could have a substantial impact on conclusion. Furthermore the analyst should conduct multiway sensitivity analyses for important parameters. Where parameter uncertainty is a major concern, a plausible range should be estimated, for example, extreme values of each key variable in the analysis, clinically meaningful range, and 95% confidence interval. Alternatively the analyst varies the parameter over a range to determine at what values of the parameter major changes in conclusion are warranted. When there is substantial uncertainty other than parameter uncertainty, the analyst may need to use simulation in a substantially more sophisticated way.
As previously mentioned, because there is likely to be significant uncertainty around the inputs, for example, diffusion rate and probability of redeploying resources, it would be wise to allow for them to be varied in any interactive model.
Detailed Remarks
Data on a pharmaceutical agent and its use . The BIA must include data on the preparation's name, ATC (anatomic, therapeutic, chemical) classification, and date of approval for use in Poland; include information of efficacy and safety; and be based on the accepted supplementary protection certificate (SPC). It must specify in the indication's description whether the indication in its entirety or only parts of the indication is or are most relevant for reimbursement and which parts of the indication the analysis concerns. It must describe daily doses and expected treatment period, as well as anticipated frequency of repetition of treatments, if relevant. It should state which others drugs or forms of medical treatment could be expected to be used concomitantly. If the treatment is expected to result in a reduction in the use of other drugs or additional therapy, this should be specified and reasons should be given. The names of drugs that, after inclusion of suggested drug on the reimbursement list, are likely to be used less often in the target population because of therapeutic indications, side effects of the current therapy, and interactions that will limit or increase comedication should be indicated.
Estimation of the use of the proposed drug . The estimated use of the drug to be reimbursed in each of the first 2 years starting from the date of placing the drug on the reimbursed drugs list should be included in BIA. The probable number of patients eligible for the proposed drug, the daily dosage, the estimated time of treatment, and if necessary, the frequency of repeating the treatment should be considered.
The probable number of patients taking a proposed drug and its therapeutic substitutes should be based on epidemiological data, such as prevalence and incidence. If treatment is expected to last up to 1 or 2 years, this will be most accurately reflected in the annual incidence of the disease. In the case of drugs to treat more chronic conditions, estimates of the prevalence of the disease are more appropriate. If the extension of survival is expected, it may be necessary to consider the increase of the prevalence of a given illness.
The expected number of patients for each of the suggested indications for the reimbursement should be estimated separately and these estimates should be summed. These data are the basis for the estimate of the likely prescription volumes of the proposed drug at least during each of the first 2 years from the date of placing the drug on the list of reimbursed drugs. These estimates should then be modified to establish the likely market share of the proposed drug. The main factors, which should be considered in this case, are the substitution of other drugs and the induced demand.
The estimation of the use of other drugs . The changes in the extent of use of other drugs, which result from placing the drug on the reimbursed drugs list, should be estimated in the BIA. This pertains to drugs which: 1) are prescribed as a part of the treatment of the drug suggested for reimbursement and 2) will probably be used less often in the target population after placing the drug on the reimbursed drugs list because of therapeutic indications, side effects of the current treatment, and interactions.
The estimate of the usage of the abovementioned drugs should be calculated according to the method described in estimation in the use of the proposed drug.
Estimation of the impact of the decision on the reimbursement of a given drug on the health-care budget for drugs . The financial implication of the decision to reimburse a given drug for the healthcare budget for drugs can be expressed using the formula (1) where l is the drug proposed for reimbursement, i l is the expected sales (number of units) of drug l , s l is the subvention of the drug l unit from the healthcare budget for the reimbursement of drugs, k is the competitive drug for drug l , r k is the reduction in use of drug k resulting from successful reimbursement of drug l, s k is the subvention of the drug k unit from the health-care budget for the reimbursement of drugs, w is the drug coprescribed with drug l , i w is the estimated use of drug w , s w is the subvention of the drug w unit from the health-care budget for the reimbursement of drugs, n is the drug used because of side effects of drug k , r n is the reduction in use of drug n , and s n is the subvention of the drug n unit from the health-care budget for the reimbursement of drugs.
In the case of each drug up to three different subventions from the health-care budget may apply owing to three different levels of patient's copayment: lump sum, 30%, and 50%, and the binding limits.
If there is no competitive market for drug l or if drug l can be substituted by a different nonpharmaceutical treatment, it is not taken into consideration in the analysis of drugs k and n. If the alternative of drug l is "no treatment," the consequence of which is symptomatic treatment with different drugs, these drugs are described as k. Side effects can be ignored if clinical trials have shown that they are insignificant or if they are similar or the same for drugs l and k. If information from randomized controlled clinical studies is insufficient for determining the influence of side effects on the health-care budget for drugs, this should be noted in the analysis. The time horizon of the analysis should correspond to the time necessary to obtain a maximum or stable share in the market of drug l. The 1-year impact of the reimbursement of drug l on the health-care budget for drugs during this time horizon or at least during the first 2 years from the date of placing drug l on the reimbursed drugs list should be estimated. This analysis should use constant prices, no allowance for inflation, and a 5% discount rate.
Estimation of the impact of the decision on the reimbursement of a given drug on the health-care budget (as total)
. The financial implication of the decision to reimburse a given drug for the healthcare budget can be expressed using the formula
where l is the drug suggested for reimbursement, k is the competitive treatment method for drug l, l is the predicted number of patients treated with drug l, k l is the cost of treatment with drug l covered by the health-care budget, rl k is the predicted decrease of the number of patients treated with k, k k is the cost of treatment with k covered by the health-care budget, and s is the savings resulting from the decrease of burden of illness by using drug l (The treatment cost includes the acquisition costs of the given drug and the drugs coprescribed with it, also owing to side effects, the cost of consultations, hospitalizations, and medical procedures that may take place while using a given drug.) The time horizon of the analysis should correspond to the time necessary to obtain a maximum or stable share in the market of drug l. The annual financial implication of the reimbursement of drug l on the health-care budget during this time horizon or at least during the first 2 years starting from the date of placing drug l on the reimbursed drugs list should be estimated. This analysis should use con-stant prices, no allowance for inflation, and an annual discount rate of 5%. The costs should be estimated based on current payments made and real financial savings obtained by the health-care budget.
Polish versus Existing Guidance on BIA
Existing guidance on BIA is limited, often unclear and variable in terms of defining what constitutes financial analysis and how it should be undertaken [23] . The most detailed guidance on BIA provides Australian guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee [4] . These guidelines specify that submission for reimbursement should "estimate the likely prescription volume of the proposed drug on the PBS for at least each of the first 2 full years from the date that it is listed on the Schedule" and "an epidemiological approach should be adopted to estimate the likely patient number projected to be eligible for the proposed drug and its comparator." In addition, any substitution effects with other reimbursed medications currently in use should be included, as should the impact on any other health-care resources, and special formulas for calculation are given. The suggested time horizon for the analysis is 2 years after launch and allows for sensitivity analysis around the rate of uptake of the therapy. The long-term effects can be considered although these may need to be reported separately. The costs should be estimated in terms of the payments actually made or the financial savings actually realized by the governments. These involve different unit prices than those recommended in health economic evaluation.
In England and Wales guidance issued by NICE (National Institute for Clinical Excellence) recommends consideration of the wider NHS implications that includes: 1) predictions of the proportion of eligible patients who might use the technology, which facilitates estimation of aggregate costs and benefits; 2) budget impact; and 3) service impact [18] . For new technologies budget impact should include estimates of the changing budget impact over a 3-to 5-year period as a result of varying diffusion rates and also an estimate of impact once diffusion has reached a steady state. This time horizon corresponds with 3-to 5-year funding agreements in the United Kingdom, announced in 1997 [25] . A similar approach had been suggested in a Hungarian proposal for methodologic guidelines for conducting economic evaluation of health-care intervention [19] . Dutch guidelines for health economic research state in addition to incremental costs and benefit, the submission for reimbursement should "also provide an insight into total costs and effects of both treatments under investigation" [16] . The calculation of the macrobudget effects still needs some clarification.
In the other countries the decision-making bodies have only recognized the need for BIA, but neither formal nor informal guidance exists. For example, in France the price is negotiated with the Comitee Economique des Produits de Sante (CEPS) on the basis of the Amelioration du Service Medical Rendu (ASMR) but also incidence/prevalence of the disease, public health concern, and drug budget to assess the budgetary impact [26] . In Spain, the budget impact is also considered during the price and reimbursing negotiation. The royal decree 271/ 1990, which regulates these processes, requires a forecast of the sales as an element for the final decision [26] . In Italy, new negotiation guidelines issued in February 2001 require submission of a costeffectiveness study, mostly for orphan and innovative drugs; pricing and reimbursement status in other countries; commitments on volume sales, discounts to hospital, etc.; payback clauses, price reductions, or delisting if sales rise above agreed levels; and data on research and manufacturing investment in Italy [26] . Sales volume and turnover will be monitored on an annual basis.
For the purposes of the Polish project, the guidelines mentioned above have been in some parts specially adapted and some points have been better clarified. From Australian guidelines the Polish project adopts epidemiological approach, time horizon, formulas for calculation, and from NICE guidelines-the guideline on service impact. The difference between Polish and other existing guidelines lies in the fact that Polish guidelines had been issued separately, to stress that financial analysis should not be regarded as a variant of the health economic analysis conducted from a financial perspective, and more attention had been drawn to general remarks, as for example, target population, probability of redeploying resources, the need for reporting results both in natural and monetary units, and the need for interactive models.
Practical Implications
The extent to which guidelines for BIA will become a useful tool for Polish medical decision-makers remains to be seen. BIA is positioned as complementary to health economic analysis. Both of them are indispensable to provide decision-makers with reliable and good quality information. Nevertheless, both of these can give contradictory messages to decision-makers, when, for example, the costeffectiveness of the drug improves as the number who benefits increases. Ideally, to make decisionmaking process transparent, the weight of health economic evaluation and the BIA in decisionmaking process needs to be defined before formal requirements can be implemented. This approach seems to be, however, too pragmatic. In the real world difficult decisions on health-care rationing should carefully balance information on costeffectiveness, budget impact, and other factors such as ethical, equity, and other political considerations. Health-care decision-makers rarely have a single, clearly defined goal. Nevertheless, the explicit use of standard BIA guidelines creates a more transparent resource allocation process and may ultimately contribute to the development of an economically viable and sustainable health-care system. Despite uncertainties in the methodology and lack of experience in making practical use of findings, decisionmaking supported by reasonable data is superior to decision-making unsupported by such data.
